scholarly journals Nanotechnology mediated bee venom: Applications in rheumatoid arthritis

2019 ◽  
Author(s):  
Lydia Smith ◽  
Sayantan Das
BMJ Open ◽  
2014 ◽  
Vol 4 (11) ◽  
pp. e006140 ◽  
Author(s):  
Ju Ah Lee ◽  
Mi Ju Son ◽  
Jiae Choi ◽  
Ji Hee Jun ◽  
Jong-In Kim ◽  
...  

Toxicon ◽  
2005 ◽  
Vol 46 (1) ◽  
pp. 39-45 ◽  
Author(s):  
Seung-Jae Hong ◽  
Gyu Sung Rim ◽  
Hyung In Yang ◽  
Chang Shik Yin ◽  
Hyeong Gyun Koh ◽  
...  

BMJ Open ◽  
2014 ◽  
Vol 4 (4) ◽  
pp. e004602 ◽  
Author(s):  
Ju Ah Lee ◽  
Mi Ju Son ◽  
Jiae Choi ◽  
Kyung-Jin Yun ◽  
Ji Hee Jun ◽  
...  

Toxins ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 66 ◽  
Author(s):  
Andreas Aufschnaiter ◽  
Verena Kohler ◽  
Shaden Khalifa ◽  
Aida Abd El-Wahed ◽  
Ming Du ◽  
...  

Natural products represent important sources for the discovery and design of novel drugs. Bee venom and its isolated components have been intensively studied with respect to their potential to counteract or ameliorate diverse human diseases. Despite extensive research and significant advances in recent years, multifactorial diseases such as cancer, rheumatoid arthritis and neurodegenerative diseases remain major healthcare issues at present. Although pure bee venom, apitoxin, is mostly described to mediate anti-inflammatory, anti-arthritic and neuroprotective effects, its primary component melittin may represent an anticancer therapeutic. In this review, we approach the possibilities and limitations of apitoxin and its components in the treatment of these multifactorial diseases. We further discuss the observed unspecific cytotoxicity of melittin that strongly restricts its therapeutic use and review interesting possibilities of a beneficial use by selectively targeting melittin to cancer cells.


Sign in / Sign up

Export Citation Format

Share Document